Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with acute hepatitis C virus (HCV).~* Normal and Elevated serum alanine transferase (ALT) levels~* Positive serum HCV-RNA.~* Aged between 18 and 65 years.~* Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the drug. Additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and additionally for participants treated with ribavirin, for 6 months (for woman) and 7 months (for man and his partner) after treatment completion~Exclusion Criteria:~* Liver disease unrelated to HCV infection~* Hemoglobin (Hgb) \<12g/dL in women and \<13g/dL in men; white blood cells (WBC) \<3,000/uL; platelets (PLTs) \<100,000/ul~* Women with ongoing pregnancy or who are breast feeding~* History of severe psychiatric disease, especially depression~* History of neurologic disease, especially epilepsy~* History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease~* Positive anti-Human Immunodeficiency Virus (HIV) antibodies~* Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA) (\>1/80)~* Positive Hepatitis B surface antigen (HBsAg)~* History of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months~* History or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PEG-IFN 24 (Type: EXPERIMENTAL): pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
- PEG-IFN 12 (Type: EXPERIMENTAL): pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
- PEG-IFN + RVB 12 (Type: EXPERIMENTAL): pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).